REFERENCES
- Piascik MM. Research and development of drugs and biologic entities. Am JHospPharm. I991;48 (suppl. 1):S4-SI3.
- Thayer AM. First quarter was good for biotech and drug firms. Chem Engineer News. 1996;74:26–7.
- Pharmaceutical Manufacturers Association. In-development orphan drugs, annual survey. Washington, DC: Pharmaceutical Manufacturers Association; 1991
- Norwood CE. Pharmacoeconomic analysis for biotechnology products. Pharm Biotechnol Mon. 1991; 1:3–4.
- Shane R. Managing biotechnological drugs. Pharm Times, 1993; 59: 8HTP-12HTP.
- Iteen SA, Hayward SL. Who counter-details whom? Repositioning pharmacy in the biotechnology drug detailing process. Am Soc Hosp Pharm Midyear Clinical Meeting. 1991; 26 MCS-28 MCS.
- Rescher N. Allocation of exotic medical lifesaving therapy. Ethics 79. Chicago: University of Chicago Press; 1979.
- Engelhardt HT Jr, Rie MA. Intensive care units, scarce resources, and conflicting principles of justice. J Am Med Assoc. 1986; 255: 1159–64.
- Allen DB, Fost NC. Growth hormone therapy for short stature: panacea or Pandora;s box? J Pediatrics. 1990; 117: 16–21.
- Symons A. Pharmacy cashes in on biotech boom. Drug Store News for Pharm. 1993; 3: 31-32, 36.
- Lappe M. The best of bioethics: genetics, neuroscience, and biotechnology. Hast Cent Rep. 1990; 20(6): 21–2.
- Powledge TM. Toward the year 2000. Science supplement. November 3, 1989,8.
- Fackelmann K.A. Beyond the genome: the ethics of DNA testing. Science News. 1994; 146:298–9.
- Nirenberg MW. Will society be prepared? Science. 1967; 157: 633.
- Joint ethics working group. Hum Gene News. May 1990; NIH-DOE.
- Hamilton J. The genetic age. Business Week. May 28, 1990; 68–83.
- Smith JE. Ethical issues raised by the Human Genome Project. Am J Hosp Pharm. 1993; 50: 1945–50.
- Privacy protection given to genetic information in McDermott legislation, informed consent required. The Blue Sheet. 1996; 39 (20): 3–4.
- Ethical, legal and social implications of human genome research. The Blue Sheet. 1996; 39 (20): 7.
- Murray TH. Genetics and the moral mission of health insurance. Hast Cent Rep. 1992; 22: 12–17.
- Check WA. Impact of gene therapy on the future of pharmacy practice. Am Pharm. 1991; 31: 58-60, 63.
- Leiden JM. Gene therapy—promise, pitfalls and prognosis. N Engl J Medicine. 1995;333:871–2.
- Kessler DA, Siegel JP, Noguchi PD et al. Regulation of somatic-cell therapy and gene therapy by the food and drug administration. N Engl J Med. 1993; 329: 1169–73.
- Fletcher JC. Evolution of ethical debate about human gene therapy. Hum GeneTher. 1990; 1:55–68.
- Hoose B. Gene therapy: where to draw the line. Hum Gene Ther. 1990; 1: 299–306.